LEADER 03586nam  2200769Ia 450 
001 9910824943803321
005 20240417010345.0
010   $a1-283-63640-9
010   $a0-309-22419-5
035   $a(CKB)2670000000275073
035   $a(EBL)3379026
035   $a(SSID)ssj0000665822
035   $a(PQKBManifestationID)11422014
035   $a(PQKBTitleCode)TC0000665822
035   $a(PQKBWorkID)10646743
035   $a(PQKB)10190436
035   $a(MiAaPQ)EBC3379026
035   $a(Au-PeEL)EBL3379026
035   $a(CaPaEBR)ebr10606367
035   $a(CaONFJC)MIL394886
035   $a(OCoLC)923288397
035   $a(EXLCZ)992670000000275073
100   $a20120911d2012      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aEvolution of translational omics $elessons learned and the path forward /$fCommittee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy ; Christine M. Micheel, Sharyl J. Nass, and Gilbert S. Omenn, editors ; Institutes of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$dc2012
215   $a1 online resource (338 p.)
300   $aDescription based upon print version of record.
311   $a0-309-22418-7 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Omics-Based Clinical Discovery: Science, Technology, and Applications""; ""3 Best Practices for Omics-Based Test Validation Prior to Use for Patient Management Decisions in a Clinical Trial Setting""; ""4 Evaluation of Omics-Based Tests for Clinical Utility and Use""; ""5 Responsible Parties""; ""6 Lessons from the Case Studies""; ""Appendix A: Case Studies""
327   $a""Appendix B: Gene Expression Based Tests Developed at Duke University and Used in Clinical Trials""""Appendix C: Introduction to Biomarkers""; ""Appendix D: Reporting Guidelines""; ""Appendix E: Committee Member and Staff Biographies""; ""Appendix F: Information Gathering Sessionsand Speakers""; ""Acronyms and Abbreviations""; ""Glossary""
606   $aGenomics$xTechnology
606   $aGenomics$xData processing
606   $aGenetic translation$xTechnology
606   $aBiomolecules$xAnalysis
606   $aBiomolecules$xData processing
606   $aBioinformatics$xTechnology
606   $aBiotechnology
606   $aData mining$xAnalysis
615  0$aGenomics$xTechnology.
615  0$aGenomics$xData processing.
615  0$aGenetic translation$xTechnology.
615  0$aBiomolecules$xAnalysis.
615  0$aBiomolecules$xData processing.
615  0$aBioinformatics$xTechnology.
615  0$aBiotechnology.
615  0$aData mining$xAnalysis.
676   $a572.33
701   $aMicheel$b Christine$01613229
701   $aNass$b Sharyl J$0857626
701   $aOmenn$b Gilbert S$01656298
712 02$aInstitute of Medicine (U.S.).$bCommittee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials.
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy.
712 02$aNational Academies Press (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910824943803321
996   $aEvolution of translational omics$94116827
997   $aUNINA